Matches in SemOpenAlex for { <https://semopenalex.org/work/W2925245302> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2925245302 abstract "OBJECTIVES/SPECIFIC AIMS: The study aims to identify the short and long-term associations of HTPR and presence of CYP2C19 polymorphism in the occurrence of major adverse cardiovascular events (MACE). The primary outcome of the study will be the presence of MACE including stent thrombosis, need for revascularization, acute limb ischemia events, myocardial infarction and death in relation to the presence of HTPR and CYP2C19 polymorphism. Secondary outcomes will include the prevalence of HTPR and CYP2C19 polymorphism in patients with PAD, and association with other medications including aspirin and cilostazol. METHODS/STUDY POPULATION: Patients above 21 years of age with the diagnosis of PAD using clopidogrel therapy for at least for seven days will be recruited at the University of Puerto Rico District Hospital and Cardiovascular Hospital of Puerto Rico and the Caribbean. RESULTS/ANTICIPATED RESULTS: A total of 200 patients from Puertorrican, Dominican and Cuban ethnicity will be expected to be recruited. The most common comorbidities will include, coronary artery disease, hypertension, dyslipidemia, and diabetes mellitus type 2. No significant distr DISCUSSION/SIGNIFICANCE OF IMPACT: The status quo as it pertains to resistance to clopidogrel in PAD patients is to improve antiplatelet resistance using antiplatelet therapy guided by platelet assays in order to reduce MACE occurrence. Although HTPR and presence of CYP2C19 polymorphisms have been studied on the PAD population, currently there is no gold standard test for measuring antiplatelet resistance. In that regard, this study will expect to identify the contribution that HTPR and CYP2C19 polymorphism might have on MACE in patients with PAD. In this way, the results will allow identification of abnormality parameters in HTPR and CYP2C19 testing in relation to the impact on risk of having MACE. Once the association of these variables with MACE is established, testing for clopidogrel resistance could become a potential strategy to optimize antiplatelet therapy and reduce the impact that MACE have in this population." @default.
- W2925245302 created "2019-04-01" @default.
- W2925245302 creator A5016900636 @default.
- W2925245302 date "2019-03-01" @default.
- W2925245302 modified "2023-10-03" @default.
- W2925245302 title "3480 Association of Clopidogrel Resistance Determinants and MACE Ocurrence in Peripheral Arterial Disease" @default.
- W2925245302 doi "https://doi.org/10.1017/cts.2019.83" @default.
- W2925245302 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6799003" @default.
- W2925245302 hasPublicationYear "2019" @default.
- W2925245302 type Work @default.
- W2925245302 sameAs 2925245302 @default.
- W2925245302 citedByCount "0" @default.
- W2925245302 crossrefType "journal-article" @default.
- W2925245302 hasAuthorship W2925245302A5016900636 @default.
- W2925245302 hasBestOaLocation W29252453021 @default.
- W2925245302 hasConcept C126322002 @default.
- W2925245302 hasConcept C164705383 @default.
- W2925245302 hasConcept C2777628954 @default.
- W2925245302 hasConcept C2777698277 @default.
- W2925245302 hasConcept C2777849778 @default.
- W2925245302 hasConcept C2778096610 @default.
- W2925245302 hasConcept C2778213512 @default.
- W2925245302 hasConcept C2779134260 @default.
- W2925245302 hasConcept C2779820409 @default.
- W2925245302 hasConcept C2780739214 @default.
- W2925245302 hasConcept C2908647359 @default.
- W2925245302 hasConcept C45393284 @default.
- W2925245302 hasConcept C500558357 @default.
- W2925245302 hasConcept C71924100 @default.
- W2925245302 hasConcept C99454951 @default.
- W2925245302 hasConceptScore W2925245302C126322002 @default.
- W2925245302 hasConceptScore W2925245302C164705383 @default.
- W2925245302 hasConceptScore W2925245302C2777628954 @default.
- W2925245302 hasConceptScore W2925245302C2777698277 @default.
- W2925245302 hasConceptScore W2925245302C2777849778 @default.
- W2925245302 hasConceptScore W2925245302C2778096610 @default.
- W2925245302 hasConceptScore W2925245302C2778213512 @default.
- W2925245302 hasConceptScore W2925245302C2779134260 @default.
- W2925245302 hasConceptScore W2925245302C2779820409 @default.
- W2925245302 hasConceptScore W2925245302C2780739214 @default.
- W2925245302 hasConceptScore W2925245302C2908647359 @default.
- W2925245302 hasConceptScore W2925245302C45393284 @default.
- W2925245302 hasConceptScore W2925245302C500558357 @default.
- W2925245302 hasConceptScore W2925245302C71924100 @default.
- W2925245302 hasConceptScore W2925245302C99454951 @default.
- W2925245302 hasLocation W29252453021 @default.
- W2925245302 hasLocation W29252453022 @default.
- W2925245302 hasOpenAccess W2925245302 @default.
- W2925245302 hasPrimaryLocation W29252453021 @default.
- W2925245302 hasRelatedWork W2093540120 @default.
- W2925245302 hasRelatedWork W2380680968 @default.
- W2925245302 hasRelatedWork W2413880656 @default.
- W2925245302 hasRelatedWork W2509995913 @default.
- W2925245302 hasRelatedWork W2765101304 @default.
- W2925245302 hasRelatedWork W2766328219 @default.
- W2925245302 hasRelatedWork W2995799950 @default.
- W2925245302 hasRelatedWork W3021475824 @default.
- W2925245302 hasRelatedWork W4233636813 @default.
- W2925245302 hasRelatedWork W4251140430 @default.
- W2925245302 isParatext "false" @default.
- W2925245302 isRetracted "false" @default.
- W2925245302 magId "2925245302" @default.
- W2925245302 workType "article" @default.